A phase 1 study evaluating the safety and efficacy of DKN-01, an investigational monoclonal antibody (Mab) in patients (pts) with advanced non-small cell lung cancer.
2014 ◽
Vol 32
(15_suppl)
◽
pp. 8068-8068
◽
Keyword(s):
Phase 1
◽
2015 ◽
Vol 93
(3)
◽
pp. S86
◽